

## Due Diligence Assessment – Data Availability

<b>Part 1: General Information</b>	
<b>YODA Project (Protocol) ID:</b>	2015-0556
<b>Date:</b>	13 Aug 2015
<b>Product Name:</b>	Inflixamab (REMICADE)
<b>Therapeutic Area:</b>	Immunology
<b>Product Class:</b>	Tumor necrosis factor (TNF) blocker
<b>Condition(s) Studied:</b>	Crohn's Disease
<b>Protocol Number(s) and Title(s):</b>	C0168T67 - Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE® (infliximab) and REMICADE plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn's Disease Naive to both Immunomodulators and Biologic NCT00094458
<b>Part 2: Data Availability</b>	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	Confirmed with Merck.
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	Confirmed with Merck.
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
<b>Part 3: Data Availability Summary</b>	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes
<b>Part 4: Proposal Review</b>	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	Yes
Comments:	Yes, Janssen is in the process of performing a similar analysis.